Key facts
- It has raised $60K; the latest was Angel (individual) ($60K) in Mar 2026.
- Guardian Biomedical has filed 1 Form D with the SEC, most recently Mar 2026 ($60K sold to 1 investors).
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Guardian Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for Guardian Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Guardian Biomedical
Developer of a biosensor system designed to identify early physiological risk. The company's system identifies early physiological risks by monitoring subtle changes in the body over time rather than tracking isolated events or vital signs, it focuses on detecting physiological shifts that may signal deterioration before the onset of symptoms or emergencies, enabling users to benefit from earlier awareness, better decision-making, and more resilient care delivery.
- Sector
- Healthcare
- HQ
- Tampa, FL, United States
- Founded
- 2025
- Website
- guardianbiomedical.com/
- Ownership
- Privately Held (backing)
Guardian Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Guardian Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Guardian Biomedical in its N-PORT filings yet. We sweep new filings monthly.